Présentation de l'entreprise
Bio Green Med Solution, Inc. (BGMS) operates within the healthcare sector, specifically focusing on the biotechnology industry, where it engages in the distribution and installation of protective and fire safety materials alongside the research and development of pharmaceuticals. The company's operational scope encompasses trading and the deployment of fire protection systems, distinguishing it through a dual focus on safety equipment logistics and drug development initiatives. With a market capitalization of $5.46M, the enterprise represents a small-cap entity within the broader healthcare landscape, while its reported annual revenue stands at $747,000. The absence of specific employee count data (N/A) limits precise headcount analysis, yet the combination of a sub-$6M market cap and less than $1M in revenue indicates a company with limited scale and likely significant early-stage risks typical of micro-cap biotechnology firms. These financial dimensions suggest that BGMS is a niche player whose current valuation reflects high uncertainty rather than established market dominance or diversified revenue streams.
Santé financière
The company reports a trailing twelve-month revenue of $747,000 against a net income of $-14,092,000 and an EBITDA of $-8,422,000, revealing a severe structural cost burden where expenses drastically outweigh top-line generation. This substantial gap between revenue and net income highlights an aggressive burn rate common in R&D-intensive biotechnology firms, yet the magnitude of the loss suggests operational inefficiencies or significant one-time costs not fully offset by product sales. Free cash flow stands at $-10,077,875, indicating that the company consumes cash faster than it generates it, which severely constrains financial flexibility and necessitates external capital raises to sustain operations. Three distinct margin metrics illustrate this financial distress: the gross margin is -90.1%, the operating margin is -162.5%, and the profit margin is 0.0%, all signaling that the core business model currently fails to cover the direct costs of goods sold or generate any operational profitability. Despite these losses, the balance sheet holds $3.50M in cash against a negligible debt level of $2,000, resulting in a debt-to-equity ratio of 0.03 that characterizes the firm as highly conservative in its leverage profile. Furthermore, a current ratio of 4.70 suggests robust short-term liquidity, as current assets significantly exceed current liabilities, providing a buffer against immediate solvency pressures. However, return on equity (ROE) of -128.4% and return on assets (ROA) of -85.8% demonstrate that management is currently destroying shareholder value and utilizing assets inefficiently to generate returns.
Évaluation de la valorisation
Valuation multiples for Bio Green Med Solution, Inc. are difficult to interpret using standard profitability metrics due to the lack of earnings, as the P/E ratio (TTM) and forward P/E are both listed as N/A, implying that the market cannot value the stock based on traditional earnings multiples or that future earnings expectations are entirely speculative. Instead, investors must rely on asset-based metrics, where the price-to-book ratio of 0.78 indicates that the stock trades at a discount to its book value, which can sometimes signal undervaluation but often reflects the high risk of asset liquidation in a distressed biotech firm. Alternative valuation metrics such as the price-to-sales ratio of 7.31 and an EV/EBITDA of -0.23 further complicate the assessment, with the negative EV/EBITDA confirming that earnings are insufficient to cover enterprise value. In terms of price action, the 52-week high is $100.80 and the 52-week low is $0.73, meaning the current price sits at a level that requires careful contextualization relative to this extreme volatility range. The beta of -0.53 is a critical anomaly, suggesting that the stock price moves inversely to the broader market rather than positively correlating with it, which introduces unique volatility characteristics distinct from the average healthcare stock.
Growth & Income
Growth metrics for Bio Green Med Solution, Inc. are unavailable, with revenue growth (YoY) and earnings growth (YoY) both listed as N/A, preventing any quantitative analysis of whether earnings are growing faster or slower than revenue. Since the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%, meaning the firm retains all of its earnings to fund operations and research rather than distributing income to shareholders. This reinvestment strategy is typical for biotechnology companies in the development phase, yet the absence of positive earnings growth data prevents a confirmation of whether this reinvestment is translating into tangible commercial success or product milestones. Consequently, the overall growth and income profile remains undefined due to the lack of historical growth data and the absence of dividend income, leaving the stock's performance entirely dependent on future operational turnarounds or successful pharmaceutical developments that are not yet reflected in current financial statements.